<DOC>
	<DOCNO>NCT00614848</DOCNO>
	<brief_summary>To demonstrate safety efficacy Driver Coronary Stent coat 10 mcg/mm ABT-578 compare uncoated Driver Stent treatment single de novo lesion native coronary artery 2.25-3.5 mm diameter .</brief_summary>
	<brief_title>The ENDEAVOR II Clinical Trial : The Medtronic Endeavor Drug Eluting Coronary Stent System Coronary Artery Lesions</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>Subject acceptable candidate PTCA , stenting , emergent CABG . Subject must clinical evidence ischemic heart disease positive functional study . Subject single vessel disease multivessel disease moderate stenosis ( max 5060 % total occlusion ( 100 % ) intervention plan time study inclusion ) . Target lesion / vessel must meet following criterion : 1 . Target lesion single de novo lesion previously treat interventional procedure . Only one lesion may treat per subject 2 . Target vessel must native coronary artery stenosis &gt; =50 % &lt; 100 % 3 . Target lesion must &gt; = 14 mm ≤ 27 mm length 4 . Target vessel reference diameter must &gt; = 2.25 mm ≤3.5 mm Female subject childbearing potential must negative pregnancy test within 7 day procedure . Subject subject 's legal representative inform nature study agree provision provide write informed consent approve Institutional Review Board/Ethics Committee respective clinical site Subject treat physician agree subject comply require postprocedure followup A documented leave ventricular ejection fraction &lt; 30 % A know hypersensitivity contraindication aspirin , heparin , clopidogrel , cobalt , nickel , chromium , sensitivity contrast medium , adequately premedicated History allergic reaction significant sensitivity receive drug similar to/or synergistic ABT578 ( rapamycin , tacrolimus , sirolimus , CCI779 analogues ) . A platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ , WBC &lt; 3,000 cells/mm³ Evidence acute myocardial infarction within 72 hour intend treatment ( define : Q wave nonQ wave infarction CK enzymes &gt; 2X upper laboratory normal presence CKMB elevate Institution 's upper limit normal ) . Creatinine &gt; 2.0 mg/dl A previous coronary interventional procedure kind within 30 day prior procedure Subject require planned interventional treatment either target nontarget vessel within 30 day postprocedure Target lesion require treatment device PTCA prior stent placement Previous stenting anywhere target vessel Target vessel evidence thrombus excessively tortuous ( 2 bend &gt; 90 degree reach target lesion ) Significant ( &gt; 50 % ) stenosis proximal distal target lesion might require revascularization impede run Target lesion locate native vessel distally anastomosis vein graft LIMA Target lesion follow characteristic : 1 . Lesion location aortoostial , unprotected leave main lesion , within 5mm origin LAD , LCX , RCA 2 . Involves side branch &gt; 2.0 mm diameter 3 . Is distal 45º bend vessel 4 . Is severely calcified Unprotected leave main coronary artery disease ( obstruction great 50 % leave main coronary artery ) History stroke transient ischemic attack within prior 6 month Active peptic ulcer upper GI bleeding within prior 6 month The subject history bleed diathesis coagulopathy refuse blood transfusion Concurrent medical condition life expectancy le 12 month Any previous plan treatment antirestenotic therapy include , limited , drugeluting stent brachytherapy Currently participate investigational drug another device study complete primary endpoint clinically interfere current study endpoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>restenosis</keyword>
</DOC>